Govind TekaleEstimated reading time: 2 minutes
Candida auris, a dangerous drug-resistant fungus, has been confirmed in at least 23 U.S. states as of 2026. The fungal infection was first identified in the United States in 2013, and has proven difficult to control despite ongoing containment efforts.
Some strains of Candida auris have become resistant to all medications usually used to treat fungal infections. The CDC has labeled it an “urgent threat,” recognizing the serious implications for public health, particularly in healthcare settings where vulnerable populations are concentrated.
Texas leads the states with the highest case counts, reporting over 706 known cases as of mid-July 2026. Michigan follows with 503 cases, and Illinois reports 366 cases. The geographic spread across multiple states indicates the fungus has established itself across different regions.
Importantly, despite its spread, Candida auris remains primarily a healthcare facility concern. The risk to healthy people in the general population remains relatively low. However, hospitalized patients with compromised immune systems face significant risk.
Candida auris can survive on surfaces for extended periods before spreading to patients through catheters, breathing tubes, intravenous lines, and other medical equipment. In healthcare settings where people are already ill and their immune systems are compromised, the fungus can be deadly.
Hospital-acquired infections are particularly dangerous because patients already face other health challenges. The combination of Candida auris infection with existing serious illness can prove fatal.
A CDC review of infections from 2022-2024 found that 88 percent of clinical cases occurred in people over age 45. Most cases were in males, and the vast majority occurred in acute care hospital settings. Elderly patients and those with suppressed immune systems face the highest risk.
Healthy people who contract Candida auris may be able to fight off the infection with their own immune systems, though symptoms would still require medical attention.
Some Candida auris strains have become resistant to all major categories of antifungal medications. For patients infected with fully resistant strains, treatment options are extremely limited. Clinicians may attempt investigational therapies or combination antifungal treatment in consultation with the CDC, though success is not guaranteed. This represents a challenging scenario from a medical perspective where diagnosis is possible but pharmaceutical treatment options are severely constrained.
The CDC has issued alerts to healthcare facilities about the threat and provided guidance on infection control procedures. Hospitals are implementing enhanced cleaning protocols and careful monitoring of high-risk patients.
Research into new antifungal treatments is underway, but developing new medications takes years. In the meantime, prevention through infection control remains the primary strategy.
Candida auris represents the type of emerging infectious disease threat that public health systems must prepare for. As antibiotic and antifungal resistance increases, the threat of infections we cannot treat will grow. The Candida auris situation is a warning signal that medical science must develop new approaches to treating resistant microorganisms.
